Maureen M O'brien

List of Publications by Year
in descending order

60 papers	2,107 citations	331670 21 h-index	243625 44 g-index
71 all docs	71 docs citations	71 times ranked	2946 citing authors

#	Article	IF	Citations
1	CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia. Blood Advances, 2023, 7, 251-255.	5.2	4
2	Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies. Blood Cancer Discovery, 2022, 3, 103-115.	5.0	31
3	Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. Journal of Clinical Oncology, 2022, 40, 956-967.	1.6	42
4	Results of a phase 2, multicenter, singleâ€arm, openâ€label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia. Pediatric Blood and Cancer, 2021, 68, e28946.	1.5	3
5	Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Shortâ€course EPOCH regimens are safe and effective. Pediatric Blood and Cancer, 2021, 68, e29126.	1.5	5
6	High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial. Blood, 2021, 138, 2337-2346.	1.4	16
7	Phase 2 Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Blood, 2021, 138, 4403-4403.	1.4	0
8	Potential Impact of Treatment with Inotuzumab Ozogamicin on Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia. Blood, 2021, 138, 3824-3824.	1.4	3
9	Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL). Blood, 2021, 138, 1235-1235.	1.4	1
10	CD22 low/Bcl-2 high Expression Identifies Poor Response to Inotuzumab in Relapsed/ Refractory Acute Lymphoblastic Leukemia. Blood, 2021, 138, 614-614.	1.4	1
11	Comparison of Severe Toxicities Following High Dose Methotrexate Administration By Demographics and over Time in Pediatric Patients with Acute Lymphoblastic Leukemia. Blood, 2021, 138, 1970-1970.	1.4	0
12	A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children's Oncology Group Protocol AALL1732. Blood, 2021, 138, 3398-3398.	1.4	3
13	Defining the Optimal Treatment of First Relapse of Pediatric Relapsed Anaplastic Large-Cell Lymphoma: Clinical Trial Challenges for Rare Diagnoses. Journal of Clinical Oncology, 2020, 38, 3980-3982.	1.6	0
14	Role of blinatumomab, inotuzumab, and CAR T-cells: Which to choose and how to sequence for patients with relapsed disease. Seminars in Hematology, 2020, 57, 157-163.	3.4	11
15	Chimeric Antigen Receptor T Cell Therapy in Patients with Multiply Relapsed or Refractory Extramedullary Leukemia. Biology of Blood and Marrow Transplantation, 2020, 26, e280-e285.	2.0	35
16	How the COG is Approaching the High-Risk Patient with ALL: Incorporation of Immunotherapy into Frontline Treatment. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S8-S11.	0.4	3
17	Reducing acute kidney injury in pediatric oncology patients: An improvement project targeting nephrotoxic medications. Pediatric Blood and Cancer, 2020, 67, e28396.	1.5	12
18	Experience with ponatinib in paediatric patients with leukaemia. British Journal of Haematology, 2020, 189, 363-368.	2.5	21

#	Article	IF	Citations
19	Cutting to the Front of the Line: Immunotherapy for Childhood Acute Lymphoblastic Leukemia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e132-e143.	3.8	15
20	Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Harboring Heterogeneous Genomic Profiles Respond to Venetoclax in Combination with Chemotherapy. Blood, 2020, 136, 37-38.	1.4	8
21	Castleman disease in pediatrics: Insights on presentation, treatment, and outcomes from a twoâ€site retrospective cohort study. Pediatric Blood and Cancer, 2019, 66, e27613.	1.5	20
22	Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib. Pediatric Blood and Cancer, 2019, 66, e27618.	1.5	24
23	Significant effect of infection and food intake on sirolimus pharmacokinetics and exposure in pediatric patients with acute lymphoblastic leukemia. European Journal of Pharmaceutical Sciences, 2019, 128, 209-214.	4.0	13
24	Capped antithrombin III dosing is cost effective in the management of asparaginaseâ€associated thrombosis. Pediatric Blood and Cancer, 2019, 66, e27719.	1.5	2
25	Bortezomib reinduction chemotherapy in highâ€risk <scp>ALL</scp> in first relapse: a report from the Children's Oncology Group. British Journal of Haematology, 2019, 186, 274-285.	2.5	65
26	Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Leukemia, 2019, 33, 884-892.	7.2	158
27	V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia. Blood, 2019, 134, 3830-3830.	1.4	1
28	Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL). Blood, 2019, 134, 3873-3873.	1.4	7
29	A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621. Blood, 2019, 134, 741-741.	1.4	36
30	Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study. Blood, 2019, 134, 2649-2649.	1.4	12
31	Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance. Oncologist, 2018, 23, 52-61.	3.7	123
32	Radiation dose reduction through combining positron emission tomography/computed tomography (PET/CT) and diagnostic CT in children and young adults with lymphoma. Pediatric Radiology, 2018, 48, 196-203.	2.0	5
33	Viral surveillance using PCR during treatment of AML and ALL. Pediatric Blood and Cancer, 2018, 65, e26752.	1.5	9
34	Limitations of HLHâ€2004 criteria in distinguishing malignancyâ€associated hemophagocytic lymphohistiocytosis. Pediatric Blood and Cancer, 2018, 65, e27400.	1.5	31
35	Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Blood Cancer Journal, 2018, 8, 80.	6.2	68
36	Cost-Effectiveness Analysis of an Adherence-Promotion Intervention for Children With Leukemia: A Markov Model-Based Simulation. Journal of Pediatric Psychology, 2018, 43, 758-768.	2.1	6

#	Article	IF	Citations
37	A Phase I/Pilot Study of CPX-351 [Daunorubicin and Cytarabine Liposome for Injection (VyxeosÂ®)] for Children, Adolescents and Young Adults with Recurrent or Refractory Acute Leukemia. Blood, 2018, 132, 336-336.	1.4	0
38	Urine biomarkers of acute kidney injury in noncritically ill, hospitalized children treated with chemotherapy. Pediatric Blood and Cancer, 2017, 64, e26538.	1.5	22
39	Redefining treatment failure for pediatric acute leukemia in the era of minimal residual disease testing. Pediatric Hematology and Oncology, 2017, 34, 395-408.	0.8	1
40	Azacitidine and Sorafenib Therapy in a Pediatric Patient With Refractory Acute Myeloid Leukemia With Monosomy 7 and Somatic PTPN11 Mutation. Pediatric Blood and Cancer, 2016, 63, 551-553.	1.5	1
41	Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2016, 34, 4381-4389.	1.6	478
42	Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia. Cancer Cell, 2016, 30, 737-749.	16.8	95
43	Lineage Switch in MLLâ€Rearranged Infant Leukemia Following CD19â€Directed Therapy. Pediatric Blood and Cancer, 2016, 63, 1113-1115.	1.5	138
44	Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute Leukemia. Blood, 2016, 128, 2780-2780.	1.4	62
45	Thiopurines for the Treatment of Acute Lymphoblastic Leukemia in Children. JAMA Oncology, 2015, 1, 281.	7.1	1
46	A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Adults with Relapsed or Refractory B-Lineage Acute Leukemia (B-ALL) and Highly Aggressive Lymphoma. Blood, 2015, 126, 1328-1328.	1.4	43
47	Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition. Blood, 2015, 126, 3792-3792.	1.4	11
48	Lymphoid Lineage Preference of MLL-AF4 Is Revealed in a Species-Specific Model. Blood, 2015, 126, 2454-2454.	1.4	0
49	Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study. Haematologica, 2014, 99, 299-307.	3.5	34
50	Phase 1/2 Study in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Receiving Blinatumomab Treatment. Blood, 2014, 124, 2292-2292.	1.4	17
51	Initial Results from a Phase 2 Study of Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3703-3703.	1.4	19
52	Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma. Blood, 2014, 124, 963-963.	1.4	29
53	A Phase 1/2 Study Of Blinatumomab In Pediatric Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. Blood, 2013, 122, 70-70.	1.4	20
54	Genomic Characterization Of Histiocytic Lesions Following Pediatric T-Cell Acute Lymphoblastic Leukemia. Blood, 2013, 122, 4940-4940.	1.4	0

#	Article	IF	Citations
55	Phase I study of valspodar (PSCâ€833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2010, 54, 694-702.	1.5	26
56	Second Malignant Neoplasms in Survivors of Pediatric Hodgkin's Lymphoma Treated With Low-Dose Radiation and Chemotherapy. Journal of Clinical Oncology, 2010, 28, 1232-1239.	1.6	160
57	Myeloid Leukemia of Down Syndrome: The Results of An International Retrospective Study. Blood, 2010, 116, 2718-2718.	1.4	0
58	Pediatric Experience with Low Dose Decitabine In Very High Risk Relapsed AML.. Blood, 2010, 116, 1070-1070.	1.4	41
59	Precursor B-cell acute lymphoblastic leukemia presenting with hemophagocytic lymphohistiocytosis. Pediatric Blood and Cancer, 2008, 50, 381-383.	1.5	49
60	Cardiomyopathy in Children With Down Syndrome Treated for Acute Myeloid Leukemia: A Report From the Children's Oncology Group Study POG 9421. Journal of Clinical Oncology, 2008, 26, 414-420.	1.6	59